MichaelAndreeffMDPhD

PubMed

• A phase II trial of ipilimumab, nivolumab, or ipilimumab and nivolumab with or without azacitidine in relapsed or refractory myelodysplastic neoplasms.
  Ian M Bouligny, Guillermo Montalban-Bravo, Koji Sasaki, Naval Daver, Elias Jabbour
  Leukemia. 2024-11-17
• The multi-kinase inhibitor CG-806 exerts anti-cancer activity against acute myeloid leukemia by co-targeting FLT3, BTK, and aurora kinases.
  Guopan Yu, Weiguo Zhang, Mahesh Basyal, Yuki Nishida, Hideaki Mizumo
  Leukemia & Lymphoma. 2024-11-01
• Protocol for monitoring clonal hematopoiesis in transgenic mouse models using multispectral imaging.
  Priyanka Khanna, Lauren B Ostermann, Shayaun Khazaei, Ran Zhao, Michael Andreeff
  STAR Protocols. 2024-10-17

Journal Articles

• Integrative Genomic Analysis of Adult Mixed Phenotype Acute Leukemia Delineates Lineage Associated Molecular Subtypes  
  Koichi Takahashi, Marina Konopleva, Steven Kornblau, Hagop Kantarjian, Nitin Jain, Elias Jabbour, Courtney D DiNardo, Michael Andreeff, Nature
• NSG-S Mice for Acute Myeloid Leukemia, Yes. For Myelodysplastic Syndrome, No  
  Michael Andreeff, MD, Haematologica
• PTEN Status Is a Crucial Determinant of the Functional Outcome of Combined MEK and mTOR Inhibition in Cancer  
  Michael Andreeff, Marina Konopleva, Nature

Abstracts/Posters

• Inhibition of Mcl-1 Enhances the Efficacy of Tyrosine Kinase Inhibition in FLT3 Mutated AML and Synergizes with Venetoclax Targeting AML Stem Cells
  Michael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• AXL/Mertk Inhibitor ONO-7475 Potently Synergizes with BCL2 Inhibitor ABT-199, Overcomes ABT-199 Resistance Mechanisms, and Kills FLT3 ITD AML Cells
  Michael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Synergistic Targeting of BTK and E-Selectin/CXCR4 in the Microenvironment of Mantle Cell Lymphomas
  Michael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Dual Targeting of Mitochondrial Unfolded Protein Response and BCL2 in Acute Myeloid Leukemia
  Michael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Determinants of Outcomes of FLT3mut Acute Myeloid Leukemia with First Salvage Therapy
  Michael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Oxphos Inhibition Induces Formation of Tunneling Nanotubes in AML Cells and Facilitates Mitochondrial Transfer from BM Stroma to AML That Contributes to Microenvironme...
  Michael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Genomic Context and TP53 Allele Frequency Define Prognostic Subgroups and Response Outcomes in TP53 Mutated Myelodysplastic Syndromes
  Michael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Cage Transcriptome Analysis Reveals BCL2A1 Upregulation in FLT3-ITD/D835 Dual Mutated AML Cells Harboring Complex Co-Mutations
  Michael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Patients with Acute Myeloid Leukemia (AML) ...
  Michael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Impact of p53 Knock-Down on T-Cell Proliferation and T-Cell Mediated Cytotoxicity Against AML Cell Lines Mediated By a CD33 Specific BiTE¬ Antibody Construct
  Michael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Outcomes of Relapsed or Refractory Acute Myeloid Leukemia after Frontline Hypomethylating Agent with Venetoclax Regimens
  Michael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Dual Inhibition of MDM2 and XPO1 Synergizes to Induce Apoptosis in Acute Myeloid Leukemia Progenitor Cells with Wild-Type TP53 through Nuclear Accumulation of p53 and ...
  Michael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Inhibition of Anti-Apoptotic Mcl-1 Exerts Anti-Leukemia Activity through Modulation of Leukemia-Stromal Interactions and Metabolic Functions in AML
  Michael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Single-Cell Mapping of Stress Response and Cell Death Pathways in Acute Myeloid Leukemia Reveals Stressor-Specific Alterations and Distinct Response Patterns
  Michael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Outcomes in Molecular Subgroups and Resistance Patterns with Ten-Day Decitabine and Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia
  Michael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• TP73 As Novel Determinant of Resistance to BCL-2 Inhibition in Acute Myeloid Leukemia
  Michael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Identification of Gene Expression Signatures in Leukemia Stem Cells and Minimal Residual Disease Following Treatment of Adverse Risk Acute Myeloid Leukemia
  Michael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Updated Preliminary Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome
  Michael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• CG-806, a First-in-Class Pan-FLT3/Pan-BTK Inhibitor, Exhibits Broad Signaling Inhibition in Chronic Lymphocytic Leukemia Cells
  Michael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Dose Escalation Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
  Michael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• TP53 Deficient/Mutant AMLs Are Resistant to Individual BH3 Mimetics: High Efficacy of Combined Inhibition of Bcl-2 and Mcl-1
  Michael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II TrialClinically Relevant Abstract
  Michael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• p53 Mediated Bone Marrow Mesenchymal Stem Cell Expansion Supports Acute Myeloid Leukemia Development
  Michael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Intravital Imaging of Bright Cyan-Fluorescent AML Model Reveals Impact of CXCR4 Inhibitor on AML and Immune Cell Dynamics
  Michael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Incidence of Serious Adverse Events, Pneumonitis, Infection and Sepsis in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphom...
  Michael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Join now to see all

Lectures

• A Phase 1 Dose Escalation Study of Milademetan in Combination with 5-Azacitidine (AZA) in Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndr... 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Targeting Misfolded p53 and p53 Aggregation to Overcome Resistance to Apoptosis in Acute Myeloid Leukemia 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Diverse Landscape of TET2 Variants in MDS and AML 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Final Results of Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Acute Myeloid Leukemia Expands Osteoprogenitor Rich Niche in the Bone Marrow but Resorbs Mature Bone Causing Osteopenia/Osteoporosis in Animal Models 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Single-Cell Atlas of Driver Mutations in Acute Myeloid Leukemia (AML) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Targeting Wnt/β-Catenin and BCL-2, Two Critical Survival Factors, Synergistically Induces Apoptosis in AML Via Rac1-Mediated MCL-1 Inhibition 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Join now to see all